Immusoft logo

Immusoft

immusoft.com

Immusoft develops cell therapies that program patients’ own B cells to produce therapeutic proteins for sustained delivery. Its therapies are intended for people with rare and other diseases with significant unmet need.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2009
Type
Corporation Seattle business license
Employees
21
Registered name
Immusoft Corp Seattle business license
Stage
Series B
Members see funding amounts.
.
Founders
Matthew Scholz

Is this your organization? Claim it

Immusoft Receives $15M CIRM Grant to Advance ISP-001 Engineered B‑Cell Therapy for MPS I

Immusoft won a $15 million CIRM grant to advance ISP-001, an engineered autologous B‑cell therapy that continuously produces IDUA enzyme for treating MPS I; early Phase 1/2 results show favorable safety, successful re-dosing, and encouraging functional signals in patients. The program aims to address limitations of current MPS I treatments by providing sustained enzyme replacement via patient-derived "living biofactories."

Immusoft’s ISP Platform Achieves First Redosing of Ex Vivo CGT Without Preconditioning, Advancing ISP-001 in Phase I/IIa for MPS 1

Immusoft’s ISP platform enabled the first redosing of an ex vivo cell & gene therapy without patient preconditioning and is now adjusting doses in a Phase I/IIa trial for MPS 1 (Hurler syndrome). Redosing could let clinicians tailor therapy over time, reduce payer burden by spreading costs, and potentially maintain or restore long-term efficacy where single-dose AAV treatments cannot be repeated.

See all 7 stories, episodes and videos about Immusoft.

People

  • Sean Ainsworth
    Sean Ainsworth Executive, Executive Officer, Director, Chief Executive Officer
  • Scott McIvor Executive, Chief Development Officer

Online